Knowledge Hub
Categories:
- Allergy [1]
- Antimicrobials & infection [5]
- Autoimmune [1]
- Chemical Pathology [15]
- Endocrinology [1]
- Epidemiology [3]
- Gastrointestinal [2]
- Genetics [6]
- Genitourinary [2]
- Haematology [9]
- HIV/TB [3]
- Infectious Diseases [10]
- Neurology [4]
- Obstetric and Neonatal care [4]
- Oncology [1]
- Ophthalmology [1]
- Respiratory [2]
- Serology [3]
- Virology [38]
With regard to Designated Service Provider (DSP) Contracts the following law is pertinent for service providers who are not a DSP:
- In terms of Section 59 (2) of the Medical Schemes Act 131 of 1998 the medical scheme must pay valid invoices within 30 days of receipt thereof or advise both the member and service provider of reasons why the invoice is not valid and provide the opportunity to correct the invoice.
- Where services are in respect of medical emergencies or involuntarily obtained services for PMB conditions, the scheme has to pay for the full cost of the services provided without deduction or co-payment or limiting the tariff amount. (Regulation 8 (1) of the Medical Schemes Act no. 131 of 1998.)
- DOH notice 214 of 2021 requires that a scheme pays for services provided at the same rate and in terms of the same rules as they pay their DSPs in respect of services voluntarily obtained, whether they are PMBs or not.
- The process followed in respect of appointing a DSP is required to be fair, equitable, transparent, competitive or cost effective as required in terms of Notice 214 of the DOH.
In summary:
- The law protects the patient’s choice to use their laboratory of choice, even if it is not a DSP, and the scheme is still obliged to reimburse us at the scheme rate for valid claims.
- This is true for PMB conditions as well as non-PMB conditions.
- The medical scheme must pay valid invoices within 30 days or advise both the member and service provider of reasons why the invoice is not valid and provide the opportunity to correct invoice.
- A scheme must pay for the services provided at a tariff not less than what they would pay a DSP.
- Should any patient have a valid claim rejected because we are not a DSP, we can assist.
Mpox Update
Since May 2022, more than 97 000 cases of mpox have been reported globally from 117 countries, with 186 deaths.
Respiratory Pathogen Statistics May 2024
This report is a summary of the results obtained from various molecular respiratory panels performed across PathCare laboratories during May 2024
Antimicrobial Surveillance Data for Common Pathogens from the Eastern Cape, 2023
Surveillance is an important tool to guide empiric therapy. Here we present the PathCare susceptibility data for the Eastern Cape for common community pathogens isolated from clinical specimens in 2023.
Respiratory Pathogen Statistics April 2024
This report is a summary of the results obtained from various molecular respiratory panels performed across PathCare laboratories during April 2024
Respiratory Pathogen Statistics March 2024
This report is a summary of the results obtained from various molecular respiratory panels performed across PathCare laboratories during March 2024
GENETIC TESTING FOR HEREDITARY CARDIOMYOPATHIES AND ARRHYTHMIAS
Hereditary cardiomyopathy and arrhythmia disorders are genetically heterogeneous meaning that within each category there are multiple disease genes, and many different pathogenic (disease-causing) variants with overlapping phenotypes.
Respiratory Pathogen Statistics: February 2024
RSV detection rates increased from 4% to 8% during the reporting period but did not reach the threshold for the start of RSV season. Higher detection rates were noted in KwaZulu-Natal (18-40%), however, this was based on a relatively small number of samples tested.
GIT Pathogen Statistics
This report presents laboratory data for last quarter (December 2023 to February 2024) obtained from GIT molecular panels requested for patients via PathCare laboratories.
Pre-operative screening and the prevention of prosthetic joint infection
Prosthetic joint infection (PJI) occurs in approximately 1% of all cases of total joint arthroplasty. To mitigate this complication, pre-operative management of patient risk factors are important to improve the outcome of surgery.